摘要
目的探究2型糖尿病患者应用达格列净联合利格列汀治疗的效果。方法选取2020年1月—2024年1月宜兴市第六人民医院收治的90例2型糖尿病患者为研究对象,采用盲摸双色球法均分为观察组和对照组,各45例。对照组行利格列汀治疗,观察组在对照组治疗的基础上加用达格列净治疗。比较两组血糖水平、胰岛功能及不良反应发生情况。结果治疗后,观察组各项血糖水平均低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组空腹胰岛素、胰岛β细胞功能指数及胰岛素抵抗指数水平均优于对照组,差异有统计学意义(P均<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论达格列净联合利格利汀能够改善2型糖尿病患者的血糖水平,提高胰岛功能,且安全性较好。
Objective To explore the effect of dapagliflozin combined with linagliptin in the treatment of type 2 diabetes mellitus.Methods A total of 90 patients with type 2 diabetes mellitus treated in Yixing Sixth People's Hospital from January 2020 to January 2024 were selected as the study objects and divided into observation group and control group with 45 cases in each group by blind touch double-color ball method.The control group was treated with linagliptin,and the observation group was treated with dapagliflozin on the basis treatment of the control group.Blood glucose level,islet function and the occurrence of adverse reactions were compared between the two groups.Results After treatment,all blood glucose levels in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,fasting insulin,islet cell function index and insulin resistance index in observation group were better than those in control group,and the differences were statistically significant(all P<0.05).There was no statistical significance in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with linagliptin can improve blood glucose level and islet function in patients with type 2 diabetes mellitus with good safety.
作者
徐鸽
王燕
谈建明
XU Ge;WANG Yan;TAN Jianming(Department of Internal Medicine,Yixing Sixth People's Hospital,Yixing 214200,Jiangsu,China)
出处
《糖尿病新世界》
2024年第9期80-83,共4页
Diabetes New World Magazine
